{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:10:09Z","timestamp":1791382209824,"version":"4.3.3"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/mao.0b013e31821f7d88","type":"journal-article","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T15:54:55Z","timestamp":1307634895000},"page":"841-847","source":"Crossref","is-referenced-by-count":27,"title":["ErbB Expression, Activation, and Inhibition With Lapatinib and Tyrphostin (AG825) in Human Vestibular Schwannomas"],"prefix":"10.1097","volume":"32","author":[{"given":"Zana K.","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen F.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni K.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210212","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis.","volume":"84","author":"Evans","year":"1992","journal-title":"Q J Med"},{"key":"R2-22-20210212","first-page":"97","article-title":"Neurofibromatosis type 2: genetic and clinic features.","volume":"78","author":"Evans","year":"199","journal-title":"ENT J"},{"key":"R3-22-20210212","first-page":"722","article-title":"Conservative management of unilateral acoustic neuromas.","volume":"21","author":"Taschudi","year":"2000","journal-title":"Am J Otol"},{"key":"R4-22-20210212","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-1-59745-523-7_10","article-title":"Molecular biology of vestibular schwannomas.","volume":"493","author":"Chang","year":"2009","journal-title":"Methods Mol Biol"},{"key":"R5-22-20210212","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.mao.0000180484.24242.54","article-title":"The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level.","volume":"27","author":"Neff","year":"2006","journal-title":"Otol Neurotol"},{"key":"R6-22-20210212","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1345\/aph.1G387","article-title":"Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.","volume":"40","author":"Nelson","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R7-22-20210212","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1470-2045(03)01137-9","article-title":"Inhibitors of epidermal-growth factor receptors: a review of clinical research with a focus on non-small cell lung cancer.","volume":"4","author":"Sridhar","year":"2003","journal-title":"Lancet Oncol"},{"key":"R8-22-20210212","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/mao.0b013e31815d4429","article-title":"ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.","volume":"29","author":"Doherty","year":"2008","journal-title":"Otol Neurotol"},{"key":"R9-22-20210212","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/j.seminoncol.2004.01.005","article-title":"Targeting the HER-kinase axis in cancer.","volume":"31","author":"Gross","year":"2004","journal-title":"Semin Oncol"},{"key":"R10-22-20210212","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1200\/JCO.2007.11.8984","article-title":"Biology of interactions: antiepidermal growth factor receptor agents.","volume":"25","author":"Harari","year":"2007","journal-title":"J Clin Oncol"},{"key":"R11-22-20210212","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/MAO.0b013e31817f7398","article-title":"The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.","volume":"29","author":"Clark","year":"2008","journal-title":"Otol Neurotol"},{"key":"R12-22-20210212","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"key":"R13-22-20210212","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/ErbB2 and downstream Erk1\/2 and AKT pathways.","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"R14-22-20210212","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO.2005.12.157","article-title":"Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.","volume":"23","author":"Spector","year":"2005","journal-title":"J Clin Oncol"},{"key":"R15-22-20210212","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level.","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R16-22-20210212","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy.","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"key":"R17-22-20210212","doi-asserted-by":"crossref","first-page":"30897","DOI":"10.1074\/jbc.271.48.30897","article-title":"The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells.","volume":"271","author":"Cohen","year":"1996","journal-title":"J Biol Chem"},{"key":"R18-22-20210212","first-page":"1133","article-title":"Evidence for a role of EGF receptor in the progression of human lung carcinoma.","volume":"13","author":"Pavelic","year":"1993","journal-title":"Anticancer Res"},{"key":"R19-22-20210212","first-page":"2965","article-title":"Role of HER2\/neu in tumor progression and therapy.","volume":"61","author":"Menard","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"R20-22-20210212","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer.","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"R21-22-20210212","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14712598.7.2.257","article-title":"Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.","volume":"7","author":"Montemurro","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"R22-22-20210212","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/theoncologist.9-suppl_3-10","article-title":"Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR\/ErbB-2 inhibitor lapatinib.","volume":"9","author":"Burris","year":"2004","journal-title":"Oncologist"},{"key":"R23-22-20210212","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/bcr919","article-title":"Small molecule tyrosine kinase inhibitors.","volume":"6","author":"Lin","year":"2004","journal-title":"Breast Cancer Res"},{"key":"R24-22-20210212","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2003.09.046","article-title":"Effects of the EGFR\/HER2 kinase inhibitor GW572016 on EGFR and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","volume":"58","author":"Zhou","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-22-20210212","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.onc.1207166","article-title":"Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR\/ErbB2 kinase inhibitor GW572016.","volume":"23","author":"Xia","year":"2004","journal-title":"Oncogene"},{"key":"R26-22-20210212","first-page":"7807","article-title":"Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the ras oncogene enhances radiation resistance.","volume":"63","author":"Grana","year":"2003","journal-title":"Cancer Res"},{"key":"R27-22-20210212","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/neuonc\/noq012","article-title":"ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.","volume":"12","author":"Ammoun","year":"2010","journal-title":"Neuro Oncol"},{"key":"R28-22-20210212","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.","volume":"23","author":"Burris","year":"2005","journal-title":"J Clin Oncol"},{"key":"R29-22-20210212","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/dna.2005.24.271","article-title":"Receptor-targeted cancer therapy.","volume":"24","author":"Richter","year":"2005","journal-title":"DNA Cell Biol"},{"key":"R30-22-20210212","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","article-title":"Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.","volume":"30","author":"Medina","year":"2008","journal-title":"Clin Ther"},{"key":"R31-22-20210212","first-page":"899","article-title":"Exploiting the PI3K\/AKT pathways for cancer drug discovery.","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nature"},{"key":"R32-22-20210212","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1126\/science.1072682","article-title":"Mitogen-activated protein kinase pathways-mediated by ERK, JNK, and p38 protein kinases.","volume":"298","author":"Johnson","year":"2002","journal-title":"Science"}],"container-title":["Otology & Neurotology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MAO.0b013e31821f7d88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:49:53Z","timestamp":1620960593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00129492-201107000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mao.0b013e31821f7d88","relation":{},"ISSN":["1531-7129"],"issn-type":[{"value":"1531-7129","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}